



STRATA

SKIN SCIENCES

Driving Value in Therapeutic and Aesthetic Dermatology

Investor Presentation

December 2025

NASDAQ: SSKN

Safe Harbor Statement

This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies and objectives of management for future operations; any statements regarding product development, product extensions, product integration or product marketing; any statements regarding continued compliance with government regulations, changing legislation or regulatory environments; any statements of expectation or belief and any statements of assumptions underlying any of the foregoing. In addition, there are risks and uncertainties related to successfully integrating the products and employees of the Company, as well as the ability to ensure continued regulatory compliance, performance and/or market growth. These risks, uncertainties and other factors, and the general risks associated with the businesses of the Company described in the reports and other documents filed with the SEC, could cause actual results to differ materially from those referred to, implied or expressed in the forward-looking statements. The Company cautions readers not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to the Company and are qualified in their entirety by this cautionary statement. The Company anticipates that subsequent events and developments will cause its views to change. The information contained in this presentation speaks as of the date hereof and the Company has or undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Investment Highlights

- **Global leader in advanced laser and light-based devices delivering unmatched efficacy and safety for serious skin disorders**
- **Existing Business is Operationally Cashflow Positive**
 - Cash from operations in 2024 was \$0.2M
 - Adjusting for 1x other income from the CARES Act of \$0.9M and interest payments of \$2.0M, the underlying cash from operations was \$1.3M in 2024
- **TAM Increase of Greater than 3x on the Horizon**
 - Historic CPT code expansion to unlock >30 million in covered potential patients goes into effect January 2027
 - Indications for use include ~30 new indications for inflammatory and autoimmune skin disorders
- **Increased Reimbursement per Patient Could Significantly Enhance TAM Expansion**
 - The Company has submitted economic data to support an increase in reimbursement per treatment
- **LaserOptek Lawsuit Reduces Competition; Potential Multimillion \$\$ Damages Could Significantly Bolster Cash Position**
 - Strata sued LaserOptek for false advertising and unfair competition under the Lanham Act
 - Nov/2024 was awarded an injunction against LaserOptek

What We Do



The **XTRAC** excimer laser delivers a highly targeted therapeutic beam of UVB light to treat multiple **autoimmune disease conditions (e.g. Psoriasis, Vitiligo)**.^{1-3*} Quick and virtually painless without the troublesome side effects of other treatment options, it's simply a better way to long-lasting results.^{4-8*}



The **VTRAC Excimer Lamp System** is a state-of-the-art device with a water-cooled handpiece for maximum irradiance at 308nm. A light source, as opposed to a laser, VTRAC offers the targeted, therapeutic efficacy demonstrated by Excimer lasers, with the simplicity of design and reliability of a lamp system.



TheraClear[®]X is a non-invasive, in-office **acne treatment system** specifically designed for the treatment of **mild-to-moderate acne**. TheraClearX's **photopneumatic technology** combines vacuum with broadband light delivered through a liquid cooled hand-held delivery system.

Key Metrics

Stock Symbol	NASDAQ: SSKN
Stock Price (as of 12/8/25)	\$1.38
Shares Outstanding (as of 9/30/25)	4.2M
Market Cap	\$8.2M
Cash & Equivalents*	\$7.1M
Debt*	\$15.3M
Enterprise Value	\$16.4M
Options* Warrants*	725,976 @ \$6.13 WAEP 80,000 @ \$8.80 WAEP
Inside Ownership (%):	27%

* As of 9/30/2025

Business Model

Recurring Revenue Business Model

- Revenue achieved through fee-per-use-based recurring procedures
- Reimbursed per procedure by Medicare and private payers
- **Partnership** - Recurring revenue driven by services that include turnkey practice solutions:
 - No upfront capital expense
 - DTC marketing patient sourcing and education
 - Co-pay and reimbursement support
 - Field service technical support
 - Clinical training
 - Proprietary **Elevate 360** practice development consulting

Goals for 2025 and Beyond

- Expand reimbursed indications for use
- Improve operational efficiencies
- Higher gross margins
- Expand revenue per device = higher recurring revenues
- Achieve positive EBITDA
- Grow positive cash flow from operations
- Establish strong foundation for potential M&A transaction



~1,000 Membership Agreements with Dermatology Providers Across the U.S.



Overview
838 Partner XTRAC® clinics + >150 sold XTRAC® devices
161 TheraClear®X clinics
5 Regions / 22 Sales Territories / 1 National Accounts Manager / National Capital Manager
14 Field Service Techs
In-house call center and insurance benefits team
6 Clinical Specialists

XTRAC® Adds (Delegated)* Reimbursed Recurring Revenue for Dermatology Partners

PARTNER VALUE OF AN XTRAC PATIENT

$$\begin{array}{l}
 \mathbf{16} \\
 \text{Number of Treatments} \\
 \text{per patient}
 \end{array}
 \times
 \begin{array}{l}
 \mathbf{\$155.27} \\
 \text{Average Revenue} \\
 \text{Per Treatment}^3
 \end{array}
 =
 \mathbf{\$2,492}$$

MEDICARE REGION: NATIONAL AVERAGE

Cpt Code	Description	2025 National Average Medicare Payment Rate ¹
96920	Excimer laser treatment for psoriasis; total area less than 250 sq. cm	\$136.83
96921	Excimer laser treatment for psoriasis; total area 250 sq. cm to 500 sq. cm	\$146.21
96922	Excimer laser treatment for psoriasis; total area over 500 sq. cm	\$182.76

XTRAC LASER PHYSICIAN PARTNER UTILIZATION RATES:

# of Patients on XTRAC Treatments/ Year (Psoriasis/ Vitiligo/ Atopic Dermatitis)	25	50	100
Average # of Treatments / Patient / Year ²	16		
Total # of Treatments / Year	400	800	1600
Average Revenue Per Treatment ³	\$155.27 ³		
Physician Gross Revenue (Annual)	\$62,107	\$124,213	\$248,427

¹ Specific Medicare payment rates vary depending on geographic indices assigned by Medicare. ² At 20 (or 30) treatments per week, this represents 10 (or 15) patients in treatment (two treatments per week) at any one time. ³ Patient mix assumption: % of Patients with CPT Code 96920 (<250cm²): 33.33%; % of Patients with CPT Code 96921 (250-500cm²): 33.33%; % of Patients with CPT Code 96922 (>500cm²): 33.33%

TheraClear®X Adds (Delegated)* Reimbursed Recurring Revenue for Dermatology Partners

PARTNER VALUE OF A THERACLEARX PATIENT

$$\begin{array}{l}
 \mathbf{6} \\
 \text{Number of Treatments} \\
 \text{per patient}
 \end{array}
 \times
 \begin{array}{l}
 \mathbf{\$112.57} \\
 \text{Average Revenue} \\
 \text{Per Treatment}^3
 \end{array}
 =
 \mathbf{\$675.42}$$

MEDICARE REGION: NATIONAL AVERAGE

Cpt Code	Description	2025 National Average Medicare Payment Rate ¹
10040	Acne Surgery, which Involves the opening or removal of multiple milia, comedones, cysts and pustules.	\$112.57

¹ Specific Medicare payment rates vary depending on geographic indices assigned by Medicare.

THERACLEARX PHYSICIAN PARTNER UTILIZATION RATES:

# of Acne Patients on THERACLEARX Treatments/ Year	100	200	300
Average # of Treatments / Patient		6	
Total # of Treatments / Year	600	1200	1800
Average Revenue Per Treatment		\$112.57	
Physician Gross Revenue (Annual)	\$67,542	\$135,084	\$202,626

Financial Metrics

(All numbers below in \$'000s except for U.S. Installed Base)

	2019	2020	2021	2022	Q1-23	Q2-23	Q3-23	Q4-23	2023	Q1-24	Q2-24	Q3-24*	Q4-24	2024	Q1-25	Q2-25	Q3-25
U.S. Gross Recurring Revenue	\$ 24,590	\$ 16,901	\$ 22,071	\$ 22,271	\$ 4,735	\$ 5,057	\$ 4,883	\$ 4,947	\$ 19,622	\$ 4,578	\$ 4,735	\$ 4,813	\$ 4,871	\$ 18,996	\$ 4,086	\$ 4,652	\$ 5,012
U.S. Installed Base (XTRAC* Devices)	820	832	890	909	916	930	929	923	923	907	882	873	864	864	846	844	838
Avg Gross Recurring Revenue/Device/Qtr	\$ 7,497	\$ 5,079	\$ 6,200	\$ 6,125	\$ 5,169	\$ 5,438	\$ 5,256	\$ 5,359	\$ 5,315	\$ 5,047	\$ 5,369	\$ 5,513	\$ 5,637	\$ 5,497	\$ 4,829	\$ 5,512	\$ 5,981
Revenue, net	\$ 31,586	\$ 23,090	\$ 29,977	\$ 36,161	\$ 7,567	\$ 8,250	\$ 8,852	\$ 8,689	\$ 33,358	\$ 6,754	\$ 8,435	\$ 8,797	\$ 9,576	\$ 33,562	\$ 6,812	\$ 7,663	\$ 6,929
Cost of revenue	11,316	8,956	10,127	14,393	3,179	3,932	3,898	3,888	14,897	3,674	3,458	3,490	3,859	14,481	3,165	3,357	2,745
Gross profit	20,270	14,134	19,850	21,768	4,388	4,318	4,954	4,801	18,461	3,080	4,977	5,307	5,717	19,081	3,647	4,306	4,172
Gross margin	64.2%	61.2%	66.2%	60.2%	58.0%	52.3%	56.0%	55.3%	55.3%	45.6%	59.0%	60.3%	59.7%	56.9%	53.5%	56.2%	60.2%
Operating expenses:																	
Engineering & product devt	1,002	1,274	1,434	1,029	315	374	248	380	1,317	241	199	243	200	883	96	86	172
Selling & marketing	12,003	9,038	13,106	15,301	3,742	3,416	3,038	2,760	12,956	3,018	3,054	3,048	3,209	12,329	2,993	3,533	3,201
General & administrative	10,275	7,898	9,712	10,087	2,917	2,490	2,283	2,818	10,508	2,710	2,210	1,888	2,714	9,522	2,573	2,911	2,668
Other	-	-	-	-	-	-	-	2,284	2,284	-	-	-	3,861	3,861	-	-	(684)
Total Expenses	\$ 23,280	18,210	24,252	26,417	6,974	6,280	5,569	8,242	27,065	5,969	5,463	5,179	9,984	26,595	5,662	6,530	5,357
Operating Income	\$ (3,010)	\$ (4,076)	\$ (4,402)	\$ (4,649)	\$ (2,586)	\$ (1,962)	\$ (615)	\$ (3,441)	\$ (8,604)	\$ (2,889)	\$ (486)	\$ 128	\$ (4,267)	\$ (7,514)	\$ (2,015)	\$ (2,224)	\$ (1,173)
Non-GAAP Adj. EBITDA	\$ 3,036	\$ 1,492	\$ 1,467	\$ 2,557	\$ (759)	\$ (95)	\$ 1,291	\$ 520	\$ 957	\$ (1,279)	\$ 1,012	\$ 1,493	\$ 904	\$ 2,130	\$ (547)	\$ (762)	\$ 10
Operating cash flow	\$ 2,229	\$ 2,096	\$ 1,508	\$ (924)	\$ (817)	\$ 947	\$ (2,020)	\$ 1,371	\$ (519)	\$ (804)	\$ 591	\$ (302)	\$ 703	\$ 188	\$ (550)	\$ (1,941)	\$ (64)

*G&A reduced by ~\$1.8M for 1x accrual of state sales tax

Diverse Dermatology Market Opportunities

Psoriasis - \$20.1B¹, Vitiligo - \$1.2B², Eczema - \$11.8B³, Acne - \$5.5B⁴



30M Patients in the U.S.

Psoriasis – 8M / Vitiligo - 5M / Eczema - 18M

TheraClear[®]X
ACNE THERAPY SYSTEM



50M+ Acne Patients in the U.S.

1) Fortune Business Insights Market Report 2019; 2016-2018 historical, 2019 base year, 2020-2027 projected

2) Fortune Business Insights Market Report 2018; 2015-2017 historical, 2018 base year, 2019-2026 projected

3) Market Data Forecast Analysis Report 2020; 2020 base year, 2021-2026 projected

4) Strata Skin Sciences

Leverage Strata's Unique and Proven Business Model

- Best-in-class devices
- **Recurring revenue** driven by DTC and internally-driven, growing installed base
- Turn-key services suite for practices without an upfront capital spend

Elevate 360 Consulting - Optimizing growth through Recurring Revenue per Device

- DTC marketing in U.S. with potential 40% revenue increase /device
- More rigorous sales and marketing strategy
- Focused growth initiatives targeting double digit revenue growth and positive cash flow



Newly Expanded Indications & Enhanced Reimbursement Unlocking Growth

In May 2025, the AMA CPT Editorial Panel revised CPT codes, enabling reimbursement for 30 new indications with its the XTRAC excimer laser

Triples Strata's XTRAC Addressable Patient Population


- From ~10M (psoriasis only) to 30M+ patients covering all Inflammatory Skin Diseases, including vitiligo, atopic dermatitis, alopecia areata, and more, effective 1/1/27

Increases Economic Value for both Providers & Strata

- Clear Path to Value: **Bigger patient pool & improved economics for providers and Strata**
- **Higher per-procedure revenue potential** from proposed increases for device-related practice expense values

2025 Initiatives To Increase Growth In Recurring Revenue Per Device In The U.S. Market

- Emphasis on **higher per practice** performance through improved patient lead-to-procedure conversion and high touch, value-add support services i.e., reimbursement administration, scheduling, and enhanced process efficiencies
- **Strategic Placements** - Reduce lower performing practices, redistributing devices among growing
- **Greater Efficiency and Treatment Capacity** - Enhanced turn-key marketing, administration and reimbursement
 - **More rigorous sales and marketing** strategies and processes
 - **Increased revenue/device** - Emphasis on **DTC marketing** (social media advertising) in U.S.
- Initiatives could collectively **grow revenue** by double digit percent




Turn-Key Solutions to Ensure Practice Success



- + **No upfront capital expense**; fee-per-use business model
- + **Complete business solution** includes a suite of value-added support services to maximize practice's success

Unique Go-to-Market Strategy



Partners supported through a complete business solution model

PE-backed Group Partnership accounts represent 37% of XTRAC domestic recurring accounts

Co-op Marketing And Practice-generated Content Creates Additional Awareness



Branded promotional materials for in-office use & patient awareness

- Patient Brochures
- Counter Cards
- Waiting Room Videos



Digital branded assets for practice web page & social media platforms

- Email Blasts
- Social Media Posts



Program Awareness Co-Op Advertising



- Mailers/Postcards



20 likes
fargodermatology Xtrac is a laser used to treat... more
January 24

DTC Advertising Generates Direct and Indirect Appointments in Partner Clinics

PATIENT JOURNEY




DTC Core Driver for Recurring Revenue

DTC drives patient population in the clinic at a **2:1 ratio**, increasing organic prescribed patients (**Halo Effect**).



Domestic XTRAC[®] Installed Base Growth Drivers



As of 9/30/2025

Over 250 comeback opportunities of existing excimer laser owners

Signed strategic expansion into group clinic rollups

Within the 43 groups:

- 90 TheraClear[®]X devices
- Penetration grew from 86 in 2018 to 358 in 2024
- Group partnership accounts represent 37% of XTRAC[®] domestic recurring revenue

Increased penetration into facility locations (e.g. Kaiser, VA, and Mt. Sinai)

Representative PE Backed Groups:



3Q25 Financial Highlights

Revenue

- Total revenue \$6.9M (-21% YOY) vs. \$8.8M 3Q24, primarily due to challenging international markets; underlying demand remains strong across regions and growth expectations remain
- Global net recurring revenue \$5.5M (+3% YOY)
- US gross recurring billings per device of \$5,981 (+8.5% YOY)
- XTRAC gross US recurrent billings \$4.8M (+3% YOY) vs. \$4.6M 3Q24
- Equipment revenue of \$1.3M (-60% YOY)

Gross Profit

- Gross profit \$4.2M (60% of revenue) vs. \$5.3M 3Q24. Gross margin was flat YOY

Operating Expenses

- Operating expenses \$5.4M (-21% YOY) from 3Q24.

Cash

- \$7.1 M cash as of September 30, 2025


International Sales Operations

Total International Install Base >1,700 devices



- In-house Head of International Sales
- 51 international partner XTRAC® clinics (S. Korea, Japan) as of September 2025
- Capital equipment sales preferred model rather than U.S. turn-key
- Usage per device higher than in U.S. market
- TheraClear®X equipment sales opportunity
- Latin America & European markets untapped

International Sales



Affiliated Academic Institutions

STRATA devices are available at over 50 academic institutes that offer dermatology residency programs



XTRAC
for Psoriasis,
Vilitigo, and Eczema

XTRAC[®]: Overview



Safe, effective treatment



350+ peer-reviewed clinical studies



Psoriasis treatment is the number 1 domestic use for XTRAC[®] lasers – 80% of treatments



Opportunities exist for expanding use for other approved indications like vitiligo and eczema



Clinical support team focused on:

- In-office training
- Best practices



Indicated for Chronic Dermatological Diseases

PSORIASIS



~7.5 million

adults in the US^{1,a}

VITILIGO



~2–3 million

adults in the US²

ATOPIC DERMATITIS



~16.5 million

adults in the US³


Visible skin disorders can limit healthy psychosocial development and have profoundly negative consequences on quality of life³⁻⁵

1. Armstrong AW et al. *JAMA Dermatol.* 2021; 157(8):940-946. ^aIncludes people 20 years of age and older.
2. Gandhi K et al. *JAMA Dermatol.* 2022; 158(1):43-50.
3. Fuxench ZCC et al. *J Invest Dermatol.* 2019; 139(3):583-590.
4. Elbuluk N, Ezzedine K. *Dermatol Clin.* 2017; 35:117-128. 5. Armstrong AW, Read C. *JAMA.* 2020; 323(19):1945-1960.

Induces Apoptosis of T cells and Keratinocytes in Psoriatic Plaques

Psoriasis: Autoimmune disease that causes the skin to regenerate faster than normal; characterized by red, itchy scaly patches

XTRAC® Targeted 308nm UVB



XTRAC® Psoriasis Clinical Protocol - 6.2 treatments to PASI* 75




***PASI** – A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis Tx- treatments

1. Abrouk M et al. *Psoriasis Targets Ther.* 2016;6:165-173. 2. Esmat S et al. *Dermatol Clin.* 2017;35:171-192. 3. Oh CT et al. *Lasers Surg Med.* 2016;48(6):629-637.


Induces Melanocyte Proliferation and T cell Apoptosis in Vitiligo Patches

Vitiligo: An autoimmune condition due to a loss of melanocytes, characterized by white patches of skin losing its pigment

XTRAC® Targeted 308nm UVB




XTRAC® Vitiligo Clinical Protocol - >75% repigmentation in less than 20 treatments¹



Baseline



After 18 tx





After 21 tx

Long lasting results


- ✓ No pigment loss during 2-year follow-up²
- ✓ 80% facial repigmentation retention at 3-year follow-up³

1. Shi Q et al. *Photodermatol Photoimmunol Photomed.* 2013;29(1):27-33. 2. Esposito M et al. *Clin Exp Dermatol.* 2004;29:133-137. 3. Hong SB et al. *J Korean Med Sci.* 2005;20:273-278
2. Hadi S et al. *Photomed Laser Surg.* 2006; 24(3):354-357
3. Sethi S, Silverberg NB. *J Drugs Dermatol.* 2022;21(7):773-775.

XTRAC[®] is a Preferred Treatment for 90% of Psoriasis Patients (<10% BSA)



Source: National Psoriasis Foundation



American Academy of Dermatology Psoriasis Clinical Guideline

Has Clinical and Economic Competitive Advantage

	XTRAC®	NB-UVB	Topical Steroids	Non-Biologic Systemics	Biologics
Approximate Costs (\$)	✓ 1K-3K	3K-9K	1K-7K	1K	32K-68K
Clinical Outcomes	✓ 92%	71%	75%	48%	50-70%
Speed of Onset	✓ 5	10	3	14	12
Days of Actual Care	✓ 18	80	294	52	12-65
Remission	✓ 2.5 Months	Continued with maintenance	Continued with maintenance	Continued with maintenance	Continued with maintenance
Adverse Events	✓ Mild Temp	Mild Temp	Mild-Mod Temp –Lasting	Mild-Severe Temp – Lasting	Mild-Severe Temp – Lasting

1. Marchetti A, Bhutani T, Lockshin B, Siegel DM, Behringer F. Therapies for Psoriasis: Clinical and Economic Comparisons. J Drugs Dermatol. 2020 Nov 1;19(11):1101-1108. doi: 10.36849/JDD.2020.5510. PMID: 33196750

TheraClearX for Acne

TheraClear[®]X: Overview



Safe, effective treatment



Peer-reviewed clinical studies



Opportunities exist for expanding use for expanding the installed base to clinics using reimbursed acne surgery procedures



Clinical support team focused on:

- In-office training
- Best practices



Acne is the Most Common Skin Condition in Dermatology




- **Up to 50 Million Americans** affected annually²
- **~85%** of all adolescents experience some degree of acne from the ages of 12 to 24 years³
- **>50%** of US women experience acne in their 20s⁴
- Acne occurring in adults is increasing⁵

1. Bickers DR et al. J Am Acad Dermatol. 2006;55:490-500.
2. Tan JKL, Bhate K. Br J Dermatol. 2015;172 (Suppl 10):3-12.
3. White GM. J Am Acad Dermatol. 1998;39:S34-S37.
4. Collier CN et al. J Am Acad Dermatol. 2008;58:56-59.
5. Holzmann R, Shaker K. Skin Pharmacol Physiol. 2014;27 (Suppl 1):3-8.

Photopneumatic Technology Combines VACUUM with PULSED BROADBAND LIGHT

- Clears bacteria and follicular contents from pilosebaceous unit, C acnes are removed both mechanically and thermally from the active acne lesion. Reduces sebum production



1. Photos courtesy of Suneel Chilukuri, MD.

Addresses Limitations of Existing Acne Therapies

TheraClear®X

- ✓ Comfortable in-office treatment with no down-time
- ✓ Visible improvement of acne lesions as early as after second treatment
- ✓ Visible improvement of skin texture, pore size, and perilesional erythema after the first few treatments

Systemic and topical acne treatments

- × Are often associated with poor adherence due to forgetfulness, inconvenience, and adverse effects^{1,2}
- × Typically require 3 to 6 weeks to achieve visible improvement³
- × Can be associated with skin dryness, irritation, burning, and bleaching effects²



Treatment regimen

Initiation

4 to 6 treatments, scheduled 1-2 weeks apart

Maintenance

1 to 2 months apart as needed



Procedure

~15 minutes per treatment

No pre-treatment with topical analgesics

Comfortable with **no down time**

Can be **delegated** (depending on state laws)



Time to improvement

Visible improvement of acne lesions **as early as after second treatment**

Visible improvement of skin texture, pore size, and perilesional erythema **after the first few treatments**

1. Snyder S et al. Am J Clin Dermatol. 2014;15(2):87-94. 2. Tuchayi SM et al. Patient Pref Adherence. 2016;10:2091-2096 3. Fox L et al. Molecules. 2016;21:1063. doi:10.3390/molecules21081063. 4. Data on file. STRATA Skin Sciences.

Seasoned Management Team

Sales and Operational Dermatology Experience



Chief Executive Officer
Dr. Dolev Rafaeli



V.P. Finance
John Gillings



Chief Operating Officer
Shmuel Gov

PhotoMedex



accelmed



PhotoMedex

no!
no!



Citizens

JMP

Investment Highlights

- **Global leader in advanced laser and light-based devices delivering unmatched efficacy and safety for serious skin disorders**
- **Existing Business is Operationally Cashflow Positive**
 - Cash from operations in 2024 was \$0.2M
 - Adjusting for 1x other income from the CARES Act of \$0.9M and interest payments of \$2.0M, the underlying cash from operations was \$1.3M in 2024
- **TAM Increase of Greater than 3x on the Horizon**
 - Historic CPT code expansion to unlock >30 million in covered potential patients goes into effect January 2027
 - Indications for use include ~30 new indications for inflammatory and autoimmune skin disorders
- **Increased Reimbursement per Patient Could Significantly Enhance TAM Expansion**
 - The Company has submitted economic data to support an increase in reimbursement per treatment
- **LaserOptek Lawsuit Reduces Competition; Potential Multimillion \$\$ Damages Could Significantly Bolster Cash Position**
 - Strata sued LaserOptek for false advertising and unfair competition under the Lanham Act.
 - Nov/2024 was awarded an injunction against LaserOptek

1. [XTRAC 510K Summary](#). Published January 14, 2020.
2. Niwa Y, Hasegawa T, Ko S, et al. Efficacy of 308-nm excimer light for Japanese patients with psoriasis. *J Dermatol*. 2009;36(11):579-582.
3. Feldman SR, Mellen BG, Housman TS, et al. Efficacy of the 308-nm excimer laser for treatment of psoriasis: Results of a multicenter study. *J Am Acad of Dermatol*. 2002;46(6):900-906.
4. Taneja A, Trehan M, Taylor C. 308-nm Excimer Laser for the Treatment of Psoriasis –Induration-Based Dosimetry. *Arch Dermatol*. 2003;139(6):759-764.
5. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. *J Am Acad of Dermatol*. 2008;58:826-50.
6. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. *J Am Acad of Dermatol*. 2009;61:451-85
7. Menter A, Korman NJ, Elmets CA. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. *J Am Acad of Dermatol*. 2009;60:643-59.
8. Fikrle T and Pizinger K. The use of the 308 nm excimer laser for the treatment of psoriasis.

Thank You.

**For More
Information**

Investor Contact:

CORE IR

516-222-2560

IR@strataskin.com

STRATA
SKIN SCIENCES

www.strataskin.com

APPENDIX

STRATA
SKIN SCIENCES

Provider engagement and education and through conferences/ webinars



AAD



Global Vitiligo Foundation



CalDerm



Fall Clinical



Acquisitions to Drive Top-line Growth



January 2022

- \$1M Acquisition
- Adds attractive business segment to address \$5.5B acne market




August 2021


- \$3.7M Acquisition
- Minimal acquisition cost compared to exclusivity in external laser market

Example – NYC Metro Area XTRAC[®] Placements and DTC Leads (2H24)

Metro NYC XTRAC[®] installed base



Metro NYC 2H24 DTC Patient Leads



Psoriasis Case Study: Patient I.B., Lewisburg, PA



Treatment Room



Before



After

